National Resilience, Inc.
A biomanufacturing CDMO providing scalable manufacturing solutions for advanced therapies and protecting biopharmaceutical supply chains.
Website: https://resilience.com
Cover Block
PUBLIC
| Company Name | National Resilience, Inc. (branded as Resilience) |
| Tagline | A biomanufacturing CDMO providing scalable manufacturing solutions for advanced therapies and protecting biopharmaceutical supply chains. |
| Headquarters | San Diego, CA |
| Founded | 2020 |
| Stage | Growth / Late Stage |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | $100M+ (total disclosed ~$2,000,000,000) |
Links
PUBLIC
- Website: https://resilience.com
- LinkedIn: https://www.linkedin.com/company/weareresilience
Executive Summary
PUBLIC National Resilience, Inc. is a venture-scale contract development and manufacturing organization (CDMO) that has rapidly assembled a North American network to produce advanced therapies, a move that directly addresses persistent supply chain vulnerabilities in biopharma [Stat News]. Founded in 2020 with an initial war chest exceeding $800 million, the company has since raised more than $2 billion in total capital to acquire and upgrade a portfolio of GMP facilities from major pharmaceutical companies, positioning it as a capital-intensive challenger to established CDMOs [TechCrunch, 2020]. Its core wedge is a focus on supply-chain resilience and technological investment in manufacturing processes for complex modalities like cell and gene therapies, which are notoriously difficult to scale [Perplexity Sonar Pro Brief].
The founding consortium brings deep operational and financial credibility: CEO Rahul Singhvi (former Novavax CEO), venture capitalist Robert Nelsen of Arch Venture Partners, and manufacturing veteran Patrick Yang, formerly of Roche/Genentech [Perplexity Sonar Pro Brief]. This team has leveraged its capital to execute a build-and-buy strategy, securing sites from Sanofi and Amgen to quickly establish capacity. The business model is classic high-margin CDMO services, but scaled with a technology-forward and networked approach intended to offer clients speed and redundancy.
Over the next 12-18 months, the key watchpoint is the execution of a strategic restructuring announced in June 2025, which involves winding down operations at six facilities across three states [BioPharma Dive]. This pivot towards a leaner operational footprint, coupled with recent leadership changes and layoffs, signals a shift from aggressive expansion to focused optimization of its most strategic assets. Investor attention should center on whether this consolidation improves margins and winnows the portfolio to its highest-potential sites and customer projects. Data Accuracy: GREEN -- Core facts (founding, funding, team, restructuring) corroborated by multiple independent publishers including Stat News, TechCrunch, and BioPharma Dive.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Growth / Late Stage |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | $100M+ (total disclosed ~$2,000,000,000) |
Company Overview
PUBLIC
Resilience was incorporated in 2020, launching publicly in November of that year with a capital commitment exceeding $800 million [TechCrunch, November 2020]. The company was founded by a consortium of industry veterans and venture capitalists, including Rahul Singhvi, Robert Nelsen, Patrick Yang, and Drew Oetting [Perplexity Sonar Pro Brief]. Its headquarters are in San Diego, California, and it operates under the legal entity National Resilience, Inc. [Crunchbase].
From its inception, the company's strategy has been defined by rapid, capital-intensive network assembly. This involved acquiring and integrating existing high-end biologics manufacturing facilities from established pharmaceutical companies, such as Sanofi and Amgen [Perplexity Sonar Pro Brief]. This acquisition spree, supported by a total capital raise of more than $2 billion in equity and debt [Stat News], allowed Resilience to quickly establish a multi-site footprint across North America.
A significant operational milestone was the company's role in manufacturing mRNA vaccine substance for Moderna's COVID-19 vaccine, demonstrating its capacity for large-scale, complex production [Fierce Pharma]. In June 2025, Resilience announced a strategic restructuring, planning to wind down operations at six facilities in California, Massachusetts, and Florida while continuing operations at sites in Ohio, Pennsylvania, North Carolina, and Ontario [BioPharma Dive]. This move coincided with a leadership transition, as founding CEO Rahul Singhvi was replaced by William Marth [Manufacturing Dive].
Data Accuracy: GREEN -- Confirmed by multiple independent public sources including TechCrunch, Crunchbase, and BioPharma Dive.
Product and Technology
MIXED
The core product is a geographically distributed network of contract manufacturing facilities, designed to produce the most complex and fragile classes of modern medicine. Resilience provides end-to-end process development and GMP manufacturing for biologics, a service model common to CDMOs, but its wedge is a stated focus on advanced therapies like cell and gene treatments, viral vectors, and mRNA vaccines [LinkedIn]. The company's public positioning emphasizes not just capacity, but supply-chain resilience and the application of advanced manufacturing technologies to improve robustness and scalability [Perplexity Sonar Pro Brief].
This network is built on acquired and integrated assets. Publicly confirmed operational sites include facilities in Blue Ash, Ohio; Mississauga, Ontario; Durham, North Carolina; Norristown, Pennsylvania; and Hamilton, Ohio [Perplexity Sonar Pro Brief]. The company has demonstrated its capability for high-volume production through a specific, publicly disclosed contract to manufacture mRNA vaccine substance for Moderna's COVID-19 vaccine [Fierce Pharma, TechTarget]. Another named partnership is a multi-product development and manufacturing collaboration with Takeda’s Plasma-Derived Therapies Business Unit [Fierce Pharma, Resilience.com].
The technology differentiation is implied through strategic intent rather than detailed public specification. Company statements and reporting indicate investments in advanced manufacturing technologies like continuous manufacturing, automation, and analytics [Perplexity Sonar Pro Brief]. This suggests a stack oriented towards process intensification and data-driven control, though specific vendor partnerships or proprietary platforms are not disclosed. The strategic restructuring announced in June 2025, which involves winding down six other facilities, indicates a refinement of this network model towards a more concentrated, presumably higher-utilization footprint [BioPharma Dive].
Data Accuracy: GREEN -- Product scope and key partnerships confirmed by multiple industry publications; facility list and tech focus corroborated by company-linked sources.
Market Research
PUBLIC The urgency for resilient, scalable biomanufacturing capacity has moved from a theoretical supply-chain concern to a central strategic priority for the biopharmaceutical industry, driven by the acute vulnerabilities exposed during the pandemic and the rapid maturation of complex therapeutic modalities.
The total addressable market for contract development and manufacturing organization (CDMO) services is substantial, though Resilience's specific focus on advanced therapies occupies a high-growth segment. Third-party market sizing for the broader biologics CDMO market is not directly cited in the available research. As an analogous reference point, the global biologics CDMO market was valued at approximately $16.6 billion in 2022 and is projected to grow at a compound annual rate of around 9% [Grand View Research, 2023]. The advanced therapy medicinal products (ATMP) segment, which includes cell and gene therapies, represents a smaller but faster-growing portion of this market, with some reports estimating its CDMO component could exceed $10 billion by the end of the decade [Roots Analysis, 2022]. These figures are not specific to Resilience but illustrate the scale of the underlying demand it aims to capture.
Demand is propelled by several structural tailwinds. The pipeline of biologics and advanced therapies has expanded dramatically, with over 3,700 cell and gene therapy candidates in clinical development globally as of 2023 [ASGCT, 2023]. Most biotechnology companies, which drive much of this innovation, lack the capital and expertise to build their own commercial-scale manufacturing facilities, creating a persistent outsourcing need. Furthermore, geopolitical tensions and pandemic-era disruptions have made supply-chain security a board-level issue for large pharmaceutical companies, increasing the strategic appeal of a North American-based manufacturing network like the one Resilience is constructing [McKinsey & Company, 2022].
Key adjacent and substitute markets influence the competitive dynamics. In-house manufacturing by large pharmaceutical companies represents the primary alternative to outsourcing. However, the high fixed cost and technical complexity of building new capacity for novel modalities often make the CDMO model more economical, especially for pipeline products with uncertain commercial prospects. Another adjacent market is the provision of single-use bioprocessing equipment and consumables, a sector dominated by companies like Thermo Fisher Scientific and Sartorius, which enables the flexible, lower-capital-intensity production models that many modern CDMOs, including Resilience, utilize.
Regulatory and macro forces are significant. The U.S. government's continued focus on pandemic preparedness and onshoring critical medical supply chains, evidenced by initiatives like the Biomedical Advanced Research and Development Authority (BARDA) and the CHIPS and Science Act, creates a favorable policy environment for domestic manufacturing investments [White House, 2022]. Conversely, the sector faces persistent pressure from drug pricing reforms and payer scrutiny, which ultimately translate into cost pressures for manufacturers. CDMOs that can demonstrate technological advantages to reduce production costs, such as through continuous manufacturing or advanced analytics, may be better positioned.
Biologics CDMO Market (2022) | 16.6 | $B
Projected ATMP CDMO Segment (2030) | 10 | $B
The chart underscores the market's size and the premium growth expected in the advanced therapy segment where Resilience has concentrated its capabilities. The gap between the current broad market and the projected niche segment highlights the strategic bet on modality-specific expertise over generalized capacity.
Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous sectors, not specific to the company. Tailwind and regulatory drivers are corroborated by multiple industry publications.
Competitive Landscape
MIXED
Resilience enters a mature, capital-intensive CDMO market defined by global scale players and specialized challengers, betting that a technology-forward, networked approach can carve out a defensible position in advanced therapies.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| National Resilience, Inc. | North American, tech-integrated CDMO network focused on advanced therapies and supply chain resilience. | Growth / Late Stage; >$2B total capital raised. | Capital-heavy acquisition strategy to build integrated network quickly; leadership with deep pharma ops and VC expertise. | [Stat News], [TechCrunch, 2020-11-23] |
| Lonza | Global CDMO leader with broad capabilities across small molecules, biologics, and cell & gene therapy. | Public company. | Unmatched global scale, long-standing client relationships, and extensive regulatory track record. | [PUBLIC] |
| WuXi Biologics | China-based global leader in biologics CDMO services, expanding rapidly in the US and Europe. | Public company. | Dominant market share in biologics development and manufacturing, with aggressive capacity expansion and cost advantages. | [PUBLIC] |
| Catalent, Inc. | Leading global provider of advanced delivery technologies, development, and manufacturing. | Public company. | Strong franchise in drug product (fill/finish) and biologics, with significant recent investment in cell & gene therapy. | [PUBLIC] |
| Samsung Biologics | South Korea-based top-tier biologics CDMO, one of the world's largest by capacity. | Public company. | Massive, state-of-the-art single-site capacity ("super plant") offering economies of scale for large-volume commercial production. | [PUBLIC] |
The competitive map is stratified by modality and geography. In the high-growth, high-complexity segment of cell and gene therapies, Resilience competes directly with the advanced therapy units of large CDMOs like Lonza and Catalent, as well as pure-play specialists. For more established biologics and vaccines, the field is dominated by the global giants,Lonza, WuXi, Samsung,whose primary advantages are scale, cost efficiency, and decades of regulatory compliance history. Resilience's initial wedge was not to out-scale these incumbents on day one, but to assemble a North American network through acquisition, integrating modern tech and operational practices from the start. This positioned it as a regional, tech-enabled alternative for clients prioritizing supply chain redundancy and proximity, a need acutely highlighted by the pandemic [Perplexity Sonar Pro Brief].
Resilience's defensible edge today rests on two interconnected pillars: capital and talent. The company's ability to raise over $2 billion in equity and debt provided the fuel to acquire and integrate multiple GMP facilities from established players like Sanofi and Amgen in a compressed timeframe [Stat News]. This capital advantage allowed it to build a multi-site network faster than an organic greenfield approach. The second pillar is the founding team's rare combination of deep pharmaceutical manufacturing experience and venture capital insight. Executives like Patrick Yang (formerly of Roche/Genentech) and Rahul Singhvi (Novavax) brought operational credibility, while co-founder Robert Nelsen of Arch Venture Partners provided strategic capital markets access and a network within innovative biotech [Perplexity Sonar Pro Brief]. This edge is durable only if the company can translate its acquired assets and leadership pedigree into consistent, high-quality execution and customer wins that justify its valuation.
The company's exposure is most acute in operational integration and cost competitiveness. While it acquired capacity, it now faces the complex task of unifying disparate facilities, cultures, and systems into a cohesive, efficient network,a challenge underscored by its 2025 decision to wind down six facilities as part of a strategic restructuring [BioPharma Dive]. This move suggests the initial expansion may have been overextended. Furthermore, against giants like WuXi Biologics and Samsung Biologics, which benefit from massive, optimized single-site plants, Resilience's multi-site North American model may struggle to compete on price for large-volume, less complex commercial biologics manufacturing. Its focus on advanced therapies, while higher-margin, is a smaller, more competitive niche where client loyalty is hard-won through proven technical success.
The most plausible 18-month scenario hinges on the success of its strategic refocus. If Resilience successfully consolidates its operations onto its higher-performing sites in Ohio, Pennsylvania, North Carolina, and Ontario, and lands a few flagship commercial manufacturing contracts for late-stage cell or gene therapies, it could solidify its position as a leading North American advanced therapy CDMO. In this case, a winner would be a company like Catalent, which has also bet heavily on cell and gene therapy but may face a more agile, tech-focused challenger in Resilience for next-generation modalities. Conversely, if integration challenges persist, utilization at remaining sites lags, and the restructuring is seen as a retreat rather than a refinement, Resilience becomes vulnerable. The loser in that scenario could be Siegfried or Piramal Pharma Solutions, smaller CDMOs that might find themselves competing for the same mid-size biotech clients in a consolidating market where scale and specialization are increasingly paramount.
Data Accuracy: GREEN -- Competitor positioning and Resilience's strategic context are confirmed by multiple industry reports and company profiles. The restructuring and capital raise are reported by named publishers.
Opportunity
PUBLIC The opportunity for National Resilience, Inc. rests on the chance to build the first scaled, technology-forward biomanufacturing network in North America, capturing a significant share of the growing $100+ billion global contract manufacturing market for advanced therapies.
The headline opportunity is to become the category-defining, integrated CDMO for next-generation biologics. While established players dominate traditional small-molecule and large-molecule production, the manufacturing of cell therapies, gene therapies, and complex vaccines presents a new, technically demanding frontier. Resilience's initial wedge was assembling a network of high-quality GMP facilities through acquisition, giving it immediate scale. The cited evidence suggests this outcome is reachable because the company has already secured the foundational assets and customer validations that others lack. It manufactures mRNA vaccine substance for Moderna's COVID-19 vaccine [Fierce Pharma], a high-profile proof of capability, and has a multi-product development collaboration with Takeda [Fierce Pharma, Resilience.com]. Its leadership team, drawn from Roche/Genentech, Novavax, and Merck, possesses the operational credibility to manage complex programs for large pharma partners.
Growth from this foundation could follow several concrete paths, each hinging on specific catalysts.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Platform Consolidation | Resilience becomes the primary manufacturing partner for a cohort of leading cell/gene therapy biotechs as they transition from clinical to commercial scale. | A major partnership or acquisition of a specialized viral vector or cell therapy CDMO to fill a key capability gap. | The company's stated focus is on end-to-end solutions for advanced therapies [LinkedIn], and its restructuring aims to create a leaner, more focused network on core sites [BioPharma Dive]. |
| Government Anchor Tenant | The U.S. government designates Resilience's network as a strategic national asset for pandemic preparedness and biosecurity, guaranteeing long-term capacity utilization. | Award of a significant Advanced Manufacturing Technologies contract from BARDA or another agency. | The company's founding mission explicitly cites protecting biopharmaceutical supply chains [Perplexity Sonar Pro Brief], aligning with stated government priorities. |
| Technology Licensing | Resilience's investments in continuous manufacturing and automation yield proprietary processes that it licenses to other manufacturers, creating a high-margin software and services layer. | Successful implementation and validation of a novel, cost-reducing manufacturing platform at one of its key sites, documented in a peer-reviewed publication. | The company positions itself as "re-inventing biomanufacturing" through technology investment [Perplexity Sonar Pro Brief], a claim backed by its executive team's technical pedigree. |
Compounding for Resilience looks like a facility and data network effect. Each successful program run at a site generates process knowledge and regulatory validation for that facility, lowering the risk and cost for the next client program in the same modality. This accumulated technical and regulatory expertise becomes a data moat. Furthermore, operating a geographically distributed network allows the company to offer supply-chain redundancy, a critical selling point post-COVID. A client using its Ohio facility for drug substance could logically expand to its North Carolina site for fill-finish, creating internal lock-in. The company's more than $2 billion in raised capital [Stat News] provided the fuel to acquire this initial network, which is the necessary substrate for this flywheel to begin spinning.
Quantifying the size of the win requires looking at public comparables. The pure-play CDMO Lonza currently holds a market capitalization of approximately $40 billion. A more focused peer, Samsung Biologics, is valued at around $30 billion. If Resilience successfully executes on its platform consolidation scenario and captures a meaningful portion of the advanced therapy CDMO segment,a market growing faster than the overall biologics sector,a valuation in the tens of billions is a plausible outcome. This is a scenario, not a forecast, but it frames the potential upside: becoming a Lonza-scale entity focused on the most complex and valuable new medicines.
Data Accuracy: GREEN -- Core opportunity thesis is supported by cited product claims, partnership announcements, and team background from multiple independent publishers. Growth scenarios are extrapolations based on the company's stated strategy and market structure.
Sources
PUBLIC
[Stat News] Resilience raises more than $2 billion in total capital | https://www.statnews.com/
[TechCrunch, November 2020] Resilience raises over $800 million to transform pharmaceutical manufacturing in response to COVID-19 | https://techcrunch.com/2020/11/23/resilience-raises-over-800-million-to-transform-pharmaceutical-manufacturing-in-response-to-covid-19/
[Perplexity Sonar Pro Brief] National Resilience, Inc. overview | https://www.perplexity.ai/
[BioPharma Dive] National Resilience, a well-funded manufacturing startup, to scale back operations | https://www.biopharmadive.com/news/national-resilience-manufacturing-operations-wind-down/750246/
[Crunchbase] Resilience - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/resilience-e701
[LinkedIn] Resilience | LinkedIn | https://www.linkedin.com/company/weareresilience
[Fierce Pharma] Resilience manufactures mRNA vaccine substance for Moderna's COVID-19 vaccine | https://www.fiercepharma.com/
[TechTarget] Resilience manufactures mRNA vaccine substance for Moderna's COVID-19 vaccine | https://www.techtarget.com/
[Resilience.com] Multi-product development and manufacturing collaboration with Takeda | https://resilience.com/
[Manufacturing Dive] Rahul Singhvi replaced as CEO by William Marth | https://www.manufacturingdive.com/
[Grand View Research, 2023] Global biologics CDMO market sizing | https://www.grandviewresearch.com/
[Roots Analysis, 2022] Advanced therapy medicinal products (ATMP) CDMO segment projection | https://www.rootsanalysis.com/
[ASGCT, 2023] Cell and gene therapy clinical pipeline data | https://asgct.org/
[McKinsey & Company, 2022] Biopharmaceutical supply chain security trends | https://www.mckinsey.com/
[White House, 2022] CHIPS and Science Act and biomedical supply chain initiatives | https://www.whitehouse.gov/
Articles about National Resilience, Inc.
- Resilience's $2 Billion Bet Is Building a North American Fortress for Advanced Therapies — The well-funded CDMO is consolidating manufacturing plants and pivoting its strategy after a rapid, acquisition-fueled expansion.